Breast cancer: Zoledronic acid—more than just a bone drug

Nature Reviews Clinical Oncology 11, 564 (2014).
doi:10.1038/nrclinonc.2014.152

Authors: Aju Mathew & Adam Brufsky
Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative, highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer.

Source: Nature Clinical Practice Oncology - September 9, 2014 Category: Cancer & Oncology Authors: Aju MathewAdam Brufsky Tags: News and Views Source Type: research